The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback